Predictive Oncology terminated merger with Renovaro, leading to legal action

From GlobeNewswire: 2025-04-04 09:40:00

Renovaro Biosciences Inc. announced a Definitive Agreement with Predictive Oncology to integrate AI/ML platform technologies and core laboratory capabilities in Europe and the US. Predictive Oncology terminated the merger transaction on April 3, 2025, causing Renovaro to seek legal remedies for breach of contract. Renovaro aims to accelerate precision and personalized medicine using AI and biotechnology platforms for early diagnosis and drug discovery. Forward-Looking Statements caution investors of potential risks and uncertainties. For investor relations, contact Chris Tyson at [email protected], and for media inquiries, contact [email protected].



Read more at GlobeNewswire: Renovaro Provides Update to Definitive Agreement with